Related Experiment Video
Updated: Jun 17, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
Tumor necrosis factor-alpha-308A allele may have a protective effect for chronic hepatitis B virus infection in
Ming-Hua Zheng1, Li-Xin Qiu, Yong-Ning Xin
1Department of Infection and Liver Diseases, Liver Research Center, First Affiliated Hospital of Wenzhou Medical College, No. 2 Fuxue Lane, Wenzhou, Zhejiang, China. blueman1320@163.com
Objectives:
Previous studies on the tumor necrosis factor-alpha (TNF-alpha)-308 gene promoter polymorphism in chronic hepatitis B virus (HBV) infection have reported conflicting results.
Methods:
We carried out a meta-analysis of 21 studies in relation to the TNF-alpha-308 gene promoter, involving a total of 4230 chronic HBV infection cases and 2905 controls.
Results:
The overall meta-analysis indicated that -308A heterozygotes (GA) had a significant 27% decreased risk of developing chronic hepatitis B (CHB) (odds ratio (OR) 0.73; 95% confidence interval (CI) 0.57-0.93; p=0.012). For -308A allele homozygotes (AA) and carriers (GA+AA), the pooled odd ratios both indicated a significantly decreased risk of CHB (OR 0.28; 95% CI 0.19-0.43; p=0.0001; and OR 0.70; 95% CI 0.55-0.89; p=0.004, respectively). In subgroup analyses by ethnicity, a significantly decreased risk was associated with -308 variant genotypes (GA and AA) in Mongoloid populations in all genetic models. However, no significant associations were found in Caucasoids. Moreover, in the subgroup analyses by control group, significantly decreased risk was associated with -308 variant genotypes (GA and AA) in the group of spontaneously recovered cases in all genetic models; however, no significant associations were found in the group of healthy cases.
Conclusions:
The TNF-alpha-308A allele is a protective factor for chronic HBV infection, especially in Mongoloids.
Related Concept Videos
Hepatitis
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

